Research programme: plasminogen-related peptides - Bio-Technology General/MGH

Drug Profile

Research programme: plasminogen-related peptides - Bio-Technology General/MGH

Alternative Names: Plasminogen-related peptide research programme - Bio-Technology General/MGH; PRP research programme - BTG/Massacheussetts General Hospital; Research programme: PRP - BTG/Massacheusetts General Hospital

Latest Information Update: 28 Dec 2000

Price : $50

At a glance

  • Originator Massachusetts General Hospital
  • Developer Massachusetts General Hospital; Savient Pharmaceuticals
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 28 Dec 2000 Discontinued-Preclinical for Solid tumours in USA (Unknown route)
  • 28 Dec 2000 Discontinued-Preclinical for Solid tumours in Israel (Unknown route)
  • 30 Jul 1999 Preclinical development for Solid tumours in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top